Objective:To evaluated a new fluorescent quantitative PCR method for HBV cccDNA.Methods:The specimens were obtained by hepatic puncturation.We designed a pair of specific primers to amplify not HBV genome but cccDNA as a method to detect it

using the ATP dependent Dnase to increase the specificity greatly.Results:We have established a new fluorescent quantitative PCR method for HBV cccDNA successfully

the linear range is from 2.5×101to 2.69×109copies per milliliter.The three of five patients were shown HBV positive and the other two were negative using the new method to analyze hepatic puncturation specimens.The HBV positive patients have all received one year long anti-virus therapy.1) the two HBV negative patients were both cccDNA negative and tDNA negative.2) the patient who has received one year long Lamivudine therapy had a DNA concentration of 7.10×103copies tDNA per milliliter serum and 2.64×103copies cccDNA per milliliter serum.The patient who has received one year long entecavir therapy had a DNA concentration of 1.0×105copies tDNA per milliliter serum and 4.04×103copies cccDNA per milliliter serum in his blood.tDNA concentration in the third patient was 6.62×103copies per milliliter serum

3.3×102copies cccDNA per milliliter serum before anti-virus therapy

but after one year long Lamivudine therapy

the tDNA and cccDNA concentration reduced to 5.19×103copies and 1.51×102copies per milliliter serum respectively.Conclusion:This study shown that the fluorescent quantitative PCR had a good linear range

high sensitivity

specificity and accuracy

so it needs less specimen

for example 100 milligram hepatic puncturation specimen is enough.Although further study is needed

the fluorescent quantitative PCR will definitely become an efficient tool for anti-virus therapeutic effect monitoring because of its high sensitivity

specificity

efficiency and accuracy.